Dezima Pharma

Dezima Pharma is a biotechnology company developing innovative drugs in the field of dyslipidemia. The company's lead product DEZ-001 (previously TA-8995) has been in-licenced from Mitsubishi Tanabe Pharma Corporation and is a potentially best-in-class CETP inhibitor.

The Company, based in Naarden, in The Netherlands was founded in 2012 by Forbion Capital Partner and BioGeneration Ventures.